Evidence map›Paper›PMID 29368638›Full record

ReviewJournal for immunotherapy of cancer2018

Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.

Jason Zhu, Andrew J Armstrong, Terence W Friedlander, Won Kim, Sumanta K Pal, Daniel J George, Tian Zhang

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal for immunotherapy of cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04706598 (A Phase I/II Single Arm Study of Intravesical Administration With Camrelizumab for High-risk Non-muscle Invasive Bladder Cancer), which is not on this map. Cited by 86 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 2 pooled it
21.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04706598 phase1 / phase2active not recruitingnot on this mapstarted 2021, after this paper: background citation

A Phase I/II Single Arm Study of Intravesical Administration With Camrelizumab for High-risk Non-muscle Invasive Bladder Cancer(NMIBC) Failing in BCG Treatment

TypeinterventionalSponsorFudan UniversityRan2021 to 2026Enrolled25ConditionsUrinary Bladder Neoplasms, ImmunotherapyArmsCamrelizumab
3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 2 syntheses or guidelines pooled it, 152 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Observational
  8. Review
  9. Article
  10. Novel PD-L1 Small-Molecule Inhibitors Advancing Cancer Immunotherapy.Anti-cancer agents in medicinal chemistry · 2026
    Review
  11. Review
  12. Review
  13. Progressive accumulation of circulating CD27Experimental & molecular medicine · 2025
    Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Jason ZhuDuke University Health System, Durham, NC, USA.
Andrew J ArmstrongDuke Cancer Institute, DUMC 103861, Durham, NC, 27710, USA.
Terence W FriedlanderUniversity of California San Francisco, San Francisco, CA, USA.
Won KimUniversity of California San Francisco, San Francisco, CA, USA.
Sumanta K PalCity of Hope Comprehensive Cancer Center, Los Angeles, CA, USA.
Daniel J GeorgeDuke Cancer Institute, DUMC 103861, Durham, NC, 27710, USA.
Tian ZhangDuke Cancer Institute, DUMC 103861, Durham, NC, 27710, USA. tian.zhang2@duke.edu.ORCID 0000-0001-8914-3531
Cancer Institute (WIA) · INUniversity of California, San Francisco · USCity of Hope · USDuke University Health System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors targeting the PD-1 pathway have greatly changed clinical management of metastatic urothelial carcinoma and metastatic renal cell carcinoma. However, response rates are low, and biomarkers are needed to predict for treatment response. Immunohistochemical quantification of PD-L1 was developed as a promising biomarker in early clinical trials, but many shortcomings of the four different assays (different antibodies, disparate cellular populations, and different thresholds of positivity) have limited its clinical utility. Further limitations include the use of archival specimens to measure this dynamic biomarker. Indeed, until PD-L1 testing is standardized and can consistently predict treatment outcome, the currently available PD-L1 assays are not clinically useful in urothelial and renal cell carcinoma. Other more promising biomarkers include tumor mutational burden, profiles of tumor infiltrating lymphocytes, molecular subtypes, and PD-L2. Potentially, a composite biomarker may be best but will need prospective testing to validate such a biomarker.

Indexed as

Biomarkers, TumorCarcinoma, Renal CellHumansImmunotherapyKidney NeoplasmsMutationProgrammed Cell Death 1 ReceptorTumor BurdenUrinary Bladder NeoplasmsBiomarkers, TumorProgrammed Cell Death 1 ReceptorBiomarkersImmune checkpoint inhibitionPD-L1Renal cell carcinomaUrothelial carcinoma

Identifiers

PMID29368638
PMCPMC5784676
OpenAlexW2783970157

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.